STTK (Shattuck Labs) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STTK Shattuck Labs Inc STTK
42 GF Score
Price $7.42
GF Value $1.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shattuck Labs Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STTK
42GF Score
Shattuck Labs Inc STTK
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shattuck Labs (STTK) Overvalued in 2026?

Based on GuruFocus' analysis, Shattuck Labs stock appears to be overvalued. The current stock price of $7.42 is trading 606.7% above its estimated GF Value™ of $1.05. GuruFocus considers Shattuck Labs to be Significantly Overvalued.

Key valuation signals for STTK:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $1.05 vs. price of $7.42 (606.7% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the STTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shattuck Labs Business Description

Address 500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
42GF Score

Get the complete analysis for STTK

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.42
Price
$1.05
GF Value